| __timestamp | Bio-Techne Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 30945000 | 46425000 |
| Thursday, January 1, 2015 | 40853000 | 81491000 |
| Friday, January 1, 2016 | 45187000 | 94291000 |
| Sunday, January 1, 2017 | 53514000 | 121827000 |
| Monday, January 1, 2018 | 55329000 | 160524000 |
| Tuesday, January 1, 2019 | 62413000 | 200000000 |
| Wednesday, January 1, 2020 | 65192000 | 275000000 |
| Friday, January 1, 2021 | 70603000 | 328100000 |
| Saturday, January 1, 2022 | 87140000 | 463800000 |
| Sunday, January 1, 2023 | 92493000 | 565000000 |
| Monday, January 1, 2024 | 96664000 | 731100000 |
Data in motion
In the competitive landscape of biotechnology, strategic investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, Neurocrine Biosciences, Inc. and Bio-Techne Corporation have demonstrated contrasting approaches to R&D spending. Since 2014, Neurocrine Biosciences has consistently increased its R&D budget, with a remarkable 1,100% growth by 2023, peaking at 565% of its 2014 expenditure. This aggressive investment underscores their commitment to pioneering new therapies and maintaining a competitive edge.
Conversely, Bio-Techne Corporation has adopted a more conservative strategy, with a 212% increase in R&D spending over the same period. Their steady growth reflects a balanced approach, focusing on sustainable innovation. Notably, 2024 data for Neurocrine Biosciences is unavailable, suggesting potential strategic shifts. These trends highlight the diverse strategies within the biotech sector, emphasizing the importance of tailored R&D investments.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Novartis AG and Bio-Techne Corporation
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
R&D Insights: How Bio-Techne Corporation and Lantheus Holdings, Inc. Allocate Funds
Research and Development Investment: Bio-Techne Corporation vs CRISPR Therapeutics AG